Home Tags Posts tagged with "Blood"
Tag:

Blood

Health

Asymmetric Resilience in Cardiac Arrest Dynamics and Prognostic Value of Surface ECG

by Claire Donovan
written by Claire Donovan

Asymmetric Resilience in Cardiac Arrest Dynamics

Research conducted by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) has uncovered critical disparities in how the heart’s chambers respond to the cessation of blood flow during ventricular fibrillation (VF). The study reveals that the right ventricle possesses a significantly higher tolerance for ischemia-the restriction of blood supply and oxygen-compared to the left ventricle, which is primarily responsible for pumping blood to the brain and the rest of the body.

This biological asymmetry results in the preservation of native electrical activity in the right ventricle for longer periods during a cardiac arrest event. These differences are particularly evident between the epicardium, the outer surface of the heart, and the endocardium, its inner lining. The resulting electrical activation gradients serve as a biological marker for the progression of organ damage during the crisis and, critically, can be read from the body surface using standard clinical equipment.

“This difference generates electrical activation gradients in the heart that track the development of the underlying injury. Moreover, the surface electrocardiogram (ECG) signal during ventricular arrhythmia-associated cardiac arrest can be used to predict the likelihood of neurological recovery after hospital admission,” explains Dr. David Filgueiras Rama, leader of the Advanced Development in Arrhythmia Mechanisms and Therapy group at the CNIC. For clinicians and emergency systems, that means a tool already present in every ambulance and emergency department could become a far more powerful prognostic instrument.

Prognostic Utility of Surface Electrocardiograms

The ability to utilize surface ECGs to forecast neurological outcomes represents a potential shift in post-resuscitation clinical management. Identifying which patients are likely to recover without severe brain injury allows healthcare systems to better allocate intensive care resources, prioritize access to advanced interventions such as targeted temperature management, and manage family expectations during the critical hours following resuscitation.

“The clinical results support the prognostic value of the surface ECG in cardiac arrest caused by ventricular fibrillation, showing that it can identify those patients who are more likely to recover without severe neurological sequelae.” In practice, this could translate into evidence-based decisions on when to escalate care, when to consider transfer to specialized cardiac centers, and when continuing highly intensive treatment may no longer be clinically justified.

Beyond immediate prognosis, the research opens avenues for targeted pharmacological or mechanical interventions. Dr. Jorge García Quintanilla, a senior researcher in the CNIC group and a member of CIBERCV, adds that “the findings provide valuable information that could guide the development of therapies aimed at protecting the left ventricle and improving its resistance to ischemia during cardiac arrest.” Such strategies would aim not only to restart the heart but also to preserve the organ’s ability to sustain adequate circulation once spontaneous circulation returns.

Public Health Implications of Ventricular Fibrillation

Ventricular fibrillation remains a primary driver of sudden cardiac death globally. The systemic challenge lies in the rapid transition from arrhythmia to global ischemia, which halts the pumping of blood to the brain and other vital organs within seconds. The survival rate is heavily dependent on the speed of intervention, particularly in out-of-hospital settings where the “chain of survival”-immediate recognition, early CPR, and rapid defibrillation-is often fragmented across multiple agencies and levels of government.

Metric Impact/Statistic (Spain) Clinical Driver
Annual Sudden Cardiac Deaths Approximately 17,000 Malignant arrhythmias (VF)
Out-of-Hospital Survival Rate Below 10% Rapid onset of global ischemia
Primary Physiological Cause Disorganized electrical activity Ineffective ventricular pumping

Addressing these outcomes requires a multidisciplinary infrastructure that integrates bioengineering, cardiology, and emergency medicine with emergency medical services and health-system planners. CNIC researcher Dr. Andrés Redondo Rodríguez highlights the importance of this collaborative approach to drive innovation in a field that has seen limited progress in recent decades, despite the widespread diffusion of basic life-support training and defibrillation technology.

Infrastructure and Systemic Response to Cardiac Emergencies

The disparity between in-hospital and out-of-hospital survival rates underscores a critical need for expanded public health infrastructure and the widespread deployment of Automated External Defibrillators (AEDs). While hospital settings provide immediate access to advanced life support, community survival depends on the availability of public-access defibrillation, the speed and coordination of emergency response, and the training of lay bystanders and first responders under nationally defined standards.

Global guidance from the World Health Organization on noncommunicable diseases positions cardiovascular disease as a core priority for national health strategies, giving governments a formal framework to strengthen cardiac arrest response through legislation, funding, and mandatory planning. Within that framework, incorporating ECG-based prognostic tools into emergency clinical pathways could help align frontline decisions with broader national targets on mortality, disability, and health-system efficiency.

From a regulatory and policy perspective, the integration of predictive ECG markers into emergency protocols could refine the triage process for patients arriving at emergency departments. By quantifying the degree of cardiac resilience and predicting neurological viability, healthcare providers can implement more precise post-cardiac arrest care, reducing the economic and human cost of prolonged, futile interventions in cases with poor prognostic markers and supporting more transparent, guideline-based communication with families.

The study involved a broad network of institutional collaboration, including the Instituto de Investigación Sanitaria, Hospital Clínico San Carlos (IdISSC), the Spanish cardiovascular research network (CIBERCV), and the Universidad Politécnica de Valencia, emphasizing the necessity of integrated research frameworks to solve complex cardiovascular pathologies. As health ministries and regional authorities update their cardiac arrest strategies, such research collaborations are likely to inform not only bedside practice but also future standards for emergency care organization and investment.

0 comments
0 FacebookTwitterPinterestEmail
Health

The Shift Toward Precision Lipid Management and the Emerging Role of Lipoprotein(a) in Cardiovascular Risk

by Claire Donovan
written by Claire Donovan

The Shift Toward Precision Lipid Management

The traditional approach to managing cardiovascular health has long centered on the reduction of low-density lipoprotein (LDL) cholesterol. However, a growing body of evidence suggests that a significant portion of cardiovascular risk remains unexplained by standard lipid panels. This “residual risk” is increasingly linked to Lipoprotein(a), or Lp(a), a genetically determined particle that functions similarly to LDL but possesses an additional protein that may enhance its capacity to promote arterial blockage and clotting.

Unlike standard cholesterol levels, which are heavily influenced by diet and exercise, Lp(a) levels are predominantly inherited. This makes the condition a systemic public health challenge, as roughly 20% of the population carries elevated levels regardless of lifestyle interventions. Because high Lp(a) is often asymptomatic, it remains largely undetected within current primary care screening frameworks, leaving a substantial population vulnerable to sudden cardiovascular events. Against this backdrop, cardiology is moving from broad cholesterol management toward precision lipid strategies that match intensity of care to an individual’s genetic risk profile.

Statistical Correlations in Patient Outcomes

New analysis of data from more than 20,000 patients across three major National Institutes of Health (NIH) studies-ACCORD, PEACE, and SPRINT-provides a clearer threshold for when Lp(a) becomes a critical driver of risk. The study focused on participants aged 40 and older, utilizing a standardized assay to measure plasma samples over a median follow-up period of nearly four years.

The findings highlight a clear correlation between higher concentrations of Lp(a) and severe health outcomes, particularly for those who already suffer from heart disease. In practical terms, the data give clinicians a numerical reference point at which Lp(a) appears to shift from background factor to principal risk amplifier.

Outcome (Lp(a) ≥ 175 nmo/L) Hazard Ratio (HR) 95% Confidence Interval (CI)
Major Adverse Cardiovascular Events (MACE) 1.31 1.10-1.55
Cardiovascular Death 1.49 1.07-2.06
Stroke 1.64 1.14-2.37

While the risk of stroke and overall cardiovascular death rose significantly at the 175 nmo/L threshold, the data did not indicate a corresponding increase in the risk of myocardial infarction (heart attack). This divergence underscores that Lp(a) may be driving distinct vascular pathways, with particular relevance for cerebrovascular and mortality outcomes. Furthermore, the impact was more pronounced in patients with pre-existing heart disease, showing a Hazard Ratio of 1.30 compared to 1.18 in those without existing conditions, reinforcing the case for more intensive monitoring in secondary prevention populations.

Systemic Implications for Screening and Regulation

The identification of a specific risk threshold shifts the conversation from general awareness to the need for targeted clinical guidelines. From a public health perspective, the reliance on standard lipid panels may result in the under-diagnosis of high-risk genetic profiles. Integrating Lp(a) testing into broader preventive health frameworks could allow for more precise risk stratification, ensuring that aggressive interventions are directed toward those with the highest genetic predisposition.

For health systems and payers, the findings raise concrete policy questions: Should Lp(a) testing become a once-in-a-lifetime screen similar to other genetic risk markers? At what threshold should coverage policies support advanced therapies or more frequent follow-up? Professional societies and policymakers will increasingly be pressed to translate these data into reimbursement, quality metrics, and population-level screening recommendations.

The current clinical strategy for patients with elevated Lp(a) involves the aggressive management of other modifiable risk factors, such as LDL cholesterol and hypertension, to compensate for the inherited risk. However, the regulatory landscape is evolving. The pharmaceutical pipeline is currently seeing the development of targeted therapies, including antisense oligonucleotides and siRNA, designed specifically to lower Lp(a) levels-a goal that traditional statins have largely failed to achieve. In the United States, any such products will ultimately be evaluated under the authority of the Food and Drug Administration, positioning Lp(a) as an emerging test case for how regulators balance genetic risk, surrogate endpoints, and hard outcomes in cardiovascular drug approval.

“For the first time, we can quantify the specific level of Lp(a) that puts patients at a significantly higher risk of major cardiovascular events, especially stroke and death. Regardless of age, patients can take a simple, low-cost blood test to determine whether they have this genetic condition. If elevated Lp(a) levels are detected, they should work closely with their healthcare provider to aggressively lower LDL cholesterol and manage other cardiovascular risk factors as much as possible. This knowledge is especially valuable as new targeted treatment options are on the horizon.”

Integrating Biospecimen Data into Population Health

The use of previously collected biospecimens from randomized trials allows researchers to extract new insights without the need for new, costly clinical trials. This methodology is becoming a cornerstone of evidence-based reporting in cardiology, providing a way to identify subgroups that may require different standards of care while making more efficient use of public research investments.

Future analysis is expected to target specific high-risk cohorts to determine if Lp(a) interacts differently with other comorbidities. Key areas of focus include:

  • Chronic Kidney Disease: Evaluating whether renal impairment exacerbates the pro-thrombotic and pro-inflammatory effects of Lp(a), potentially warranting earlier or more aggressive intervention.
  • Peripheral Artery Disease: Assessing the link between genetic lipid markers and limb ischemia, which could influence surgical decision-making and long-term antithrombotic strategies.
  • Health Equity: Analyzing how the genetic prevalence and expression of Lp(a) vary across different ancestral populations, to ensure that guideline development, trial enrollment, and future therapy access do not widen existing cardiovascular disparities.

As health ministries, regulators, and large payers confront rising cardiovascular costs, the Lp(a) story is evolving from a niche biomarker discussion into a broader test of how quickly genomic risk can be operationalized in routine care. The emerging evidence suggests that decisions made now on screening, reimbursement, and regulatory pathways will determine whether precision lipid management meaningfully reduces preventable strokes and premature deaths over the next decade.

0 comments
0 FacebookTwitterPinterestEmail
Health

Injectable Microgel Mimics Infant Clotting to Reduce Bleeding in Pediatric Surgery

by Claire Donovan
written by Claire Donovan

Biomedical engineers have created an injectable microgel designed to match the way infants form clots, reporting sizable reductions in bleeding in preclinical tests. The early work addresses a long‑standing challenge in pediatric surgery: infants do not clot like adults, yet operating rooms often must rely on blood products sourced from adults. The findings land as children’s hospitals and regulators look for safer, more tailored tools to manage bleeding in neonatal intensive care units and high‑risk surgeries.

A lab-built microgel tuned to infant clotting physiology

The team engineered B‑knob-triggered microgels (BK‑TriGs) that present short “B peptide” sequences used by fibrin-blood’s primary structural clotting protein-to build fibrin networks. The particles swell into soft hydrogels in aqueous environments, aiming to mimic key platelet‑like mechanics while concentrating the infant‑relevant peptide signals that drive clot formation. In principle, the material is meant to support the body’s own clotting processes rather than replace them, acting as a scaffold that infant clotting factors can latch onto more efficiently.

But if you give adult blood to an infant, the difference in adult hemostasis versus infant hemostasis can lead to too much clotting, that can increase the likelihood of thrombosis, where blood clots form in the lungs or elsewhere and put the baby at risk.

“My research team has done a lot of work on surgery-related bleeding in newborns, and we wanted to develop a therapeutic intervention that would reduce bleeding and – by extension – reduce the need for infants to receive adult blood transfusions during surgery,” says Brown, who is the Lampe Distinguished Professor of Biomedical Engineering in the Lampe Joint Department of Biomedical Engineering at North Carolina State University and the University of North Carolina at Chapel Hill. Brown notes that even incremental reductions in transfusion volume can matter for fragile patients weighing only a few kilograms.

What the preclinical data show so far

The early evidence for BK‑TriGs comes from controlled lab systems and animal models rather than human infants, but the signals are directionally consistent across platforms.

Model or system Intervention or comparison Observed signal
In vitro microfluidic testing with human plasma (infant and adult) BK‑TriGs exposure vs. standard conditions Improved clotting in infant plasma relative to adult plasma
Mouse model lacking endogenous fibrinogen, supplemented with infant fibrinogen (infant‑like hemostasis) BK‑TriGs vs. other options and controls 50-60% reduction in blood loss compared with controls

“We found that BK‑TriGs worked better at improving blood clotting in infant plasma than in adult plasma, which was what we expected to see,” says Brown. The microgel’s design is intended to exploit differences in infant clotting factor levels and kinetics rather than simply boosting coagulation indiscriminately.

“We found that the BK‑TriGs outperformed any of the other options we tested at reducing blood loss,” Brown adds. “Specifically, the BK‑TriGs reduced blood loss by 50-60% compared to the control group.” Those figures, while promising, come from tightly controlled experiments that cannot yet predict real‑world performance in the operating room.

Why infant clotting complicates the operating room

For surgeons and anesthesiologists, developmental differences in clotting are not just academic-they shape transfusion decisions, bypass protocols, and post‑operative monitoring. A technology that deliberately keys into infant physiology could eventually change those workflows if it proves safe and effective.

  • Developmental hemostasis: newborns have a distinct balance of pro‑ and anticoagulant proteins and fibrinolytic activity compared with adults, yielding different clotting kinetics during and after surgery.
  • Transfusion fit: operating rooms frequently rely on adult donor blood products, which can overshoot or undershoot the infant’s hemostatic needs and raise the risk of postoperative thrombosis or bleeding.
  • Exposure risks: multiple product exposures (plasma, platelets, cryoprecipitate) increase complexity in dosing and monitoring during neonatal cardiothoracic and abdominal procedures.

Pediatric professional societies have for years urged more infant‑specific evidence to guide transfusion thresholds and use of hemostatic agents. Tools like BK‑TriGs, if validated, could give hospital transfusion committees another option beyond simply adjusting adult protocols down to infant size.

Safety signals that must be addressed before any clinical use

“The results we’re reporting here are exciting, but we are still far removed from clinical use,” says Brown. “We need to make sure there are no unforeseen risks associated with blood clotting.”

  • Off‑target clotting and thrombosis: any pro‑hemostatic agent must demonstrate that it does not trigger pathologic clot formation in lungs, brain, or central lines, particularly in small‑caliber neonatal vessels.
  • Biocompatibility and immunogenicity: materials testing typically includes sterility, pyrogenicity, hemolysis, complement activation, and assessments of immune sensitization.
  • Dose finding in pediatrics: infant physiology constrains volume and dosing windows; scaling from adult paradigms is not appropriate.
  • Interaction with standard care: compatibility with blood products, anticoagulation protocols during bypass, and point‑of‑care coagulation monitoring must be established.

Any signal of unanticipated clotting in preclinical models would likely trigger additional toxicology work and close scrutiny from hospital review boards before a first‑in‑infant study could proceed.

Regulatory pathway considerations in the United States

If BK‑TriGs advance toward human use, they will move into a regulatory environment that has become more attentive to pediatric devices and biologics, but still demands extensive safety data before testing products in newborns.

  • Product classification: hemostatic technologies can be regulated as drugs, devices, biologics, or combination products; jurisdiction often depends on the product’s primary mode of action and may involve FDA centers overseeing biologics or devices.
  • Pediatric development: pediatric assessments are a formal expectation for drugs and biologics, and dedicated pathways and consortia support pediatric devices to address historically limited availability of child‑specific technologies.
  • Preclinical to first‑in‑human: typical steps include good laboratory practice (GLP) toxicology, thrombogenicity and embolic risk testing, manufacturing controls, and early feasibility protocols focused on safety and dose.

In the United States, any sponsor would ultimately need authorization from the U.S. Food and Drug Administration-most likely via an investigational new drug application or comparable investigational device exemption under the federal framework governing clinical trials-before BK‑TriGs could be tested in infants. Hospital institutional review boards would then decide how and where those trials could run, including which neonatal and cardiac surgery units participate.

Potential impact for hospitals and families if future trials succeed

For health systems, a successful infant‑tuned hemostatic product could have operational, financial, and policy repercussions, especially in high‑volume children’s hospitals that already manage strict blood‑use programs.

  • Transfusion stewardship: a therapy tuned to infant clotting could reduce intraoperative bleeding and the volume of adult blood products used in neonatal cases.
  • Operating room efficiency: fewer bleeding‑related interruptions can shorten bypass time or operative duration, with downstream effects on intensive‑care recovery and bed availability.
  • Economic considerations: decreased reliance on multiple blood components and wastage could translate into cost offsets, provided acquisition costs and monitoring demands remain manageable.

For families, fewer transfusions and shorter postoperative stays are not only clinical outcomes but also emotional and financial ones, informing decisions about where complex neonatal surgery is sought and how payers design coverage for advanced hemostatic care.

“But if we do find BK‑TriGs are safe and effective, we’re optimistic this could be a cost-effective way to make surgery safer for infants. Manufacturing the BK‑TriG particles would be relatively inexpensive – certainly in comparison to blood products.”

Equity and implementation questions that merit attention

As with many pediatric innovations, early adopters are likely to be large academic medical centers, raising questions about how quickly smaller hospitals can benefit if the technology is approved.

  • Access across NICU levels: adoption would need to reach lower‑volume and rural hospitals that stabilize newborns before transfer to tertiary centers.
  • Workforce readiness: perfusionists, anesthesiologists, and neonatal teams would require protocol training, including monitoring for thrombotic events and integration with point‑of‑care testing.
  • Data transparency: pediatric trials benefit from harmonized endpoints for bleeding and thrombosis so results are comparable across institutions.

Health systems and professional societies would ultimately decide how BK‑TriGs, or similar products, are written into perioperative guidelines and quality metrics, shaping whether they become a niche tool or a standard part of neonatal surgical care.

Funding, affiliations, and disclosures

  • Supported by the American Heart Association (22TPA969368), the National Science Foundation (2211404), and the Comparative Medicine Institute at North Carolina State University.
  • Conflicts of interest: Brown is a co‑founder of Selsym Biotech, Inc., a company developing injectable materials intended to stop bleeding.

Standard conflict‑of‑interest and funding disclosures were reported in the journal publication; hospitals and regulators will weigh those relationships alongside independent replication of the findings.

Publication and institutional details

  • Peer‑reviewed study in Science Advances published on April 3, 2026.
  • Institutional announcement by North Carolina State University provides additional nonclinical context on materials design and testing methods; see the university release.

The combination of a high‑impact journal publication and institutional backing signals that BK‑TriGs will likely remain on the radar of pediatric surgeons, regulators, and health‑system leaders as the technology moves through the long, uncertain path from laboratory to operating room.

0 comments
0 FacebookTwitterPinterestEmail
Health

Early-Stage Alzheimer’s Detection Linked to Blood Biomarker PPP2R5C Decline

by Claire Donovan
written by Claire Donovan

Early-stage Alzheimer’s signal emerges as PPP2R5C falls in blood

A research team reporting in Cell Reports Medicine identifies a decline in the neuronal regulatory subunit PPP2R5C in blood that tracks with very early Alzheimer’s biology. The work positions PPP2R5C—part of the protein phosphatase 2A (PP2A) complex central to tau dephosphorylation—as a candidate plasma biomarker linked to the processes that precede cognitive symptoms.

Why this matters for health systems and policymakers: scalable blood tests are edging closer to routine triage for cognitive complaints in primary care and memory clinics. If validated, PPP2R5C could complement existing plasma markers (p‑tau181, p‑tau217, p‑tau231) and help health systems reduce dependence on costlier positron emission tomography (PET) and invasive cerebrospinal fluid (CSF) procedures for initial assessment, reshaping how limited specialist and imaging capacity is allocated.

What the study measured

The investigation spanned neuron-derived exosomes (NDEs) and whole plasma across discovery, validation, and clinical cohorts, in both familial and sporadic Alzheimer’s disease. Key readouts are summarized below.

Cohort/Matrix Participants Primary observation Performance/readouts
Discovery (NDE proteomics) CN (n=4); pre‑FAD (n=4); FAD (n=5) PPP2R5C‑specific peptide progressively decreased from presymptomatic familial AD to symptomatic AD vs. cognitively normal. Signal directionality established across the early disease course.
Validation (targeted NDE) CN (n=32); sporadic AD (n=20); aMCI (n=12) Reduced PPP2R5C associated with early AD‑linked processes. Consistent pattern reproduced in sporadic disease.
Plasma (clinical comparison) FAD (n=15); CN (n=15) PPP2R5C significantly lower in AD than in cognitively normal controls. Demonstrated that the NDE signal can be tracked in total plasma.
Plasma (aMCI/AD vs. CN) CN; aMCI; AD Group-level PPP2R5C differences vs. CN

• aMCI: −61.3%
• AD: −31.6%
• AD vs. aMCI: −52.1%

Discrimination (AUROC) Plasma Ability to separate clinical groups

• AD vs. CN: 0.8494
• aMCI vs. CN: 0.7360
• aMCI vs. AD: 0.5931

  • Correlations: Plasma PPP2R5C aligned positively with Mini-Mental State Examination (MMSE) scores and inversely with plasma p‑tau181, p‑tau217, and p‑tau231, reinforcing relevance to tau dysregulation and cognitive status.
  • Neuropathology: Postmortem analyses showed lower brain PPP2R5C in AD versus both young and age‑matched controls. Immunohistochemistry indicated declines as early as Braak stage II, preceding extensive neurofibrillary tangle burden and supporting the notion that PPP2R5C loss is an upstream event.

Mechanistic signals mapping PPP2R5C to tau control

Together, mechanistic experiments connect the observed blood changes in PPP2R5C to intracellular pathways that regulate tau.

  • Protein–protein interactions: Co‑immunoprecipitation demonstrated direct PPP2R5C–tau interaction, supporting a structural basis for PP2A‑mediated tau dephosphorylation.
  • PP2A activation: Overexpressing PPP2R5C lowered phosphorylated and total tau while increasing PP2A activity; silencing PPP2R5C reduced PP2A activity, indicating that PPP2R5C levels modulate a core phosphatase axis implicated in Alzheimer’s pathology.
  • Clearance pathway: PPP2R5C‑driven tau reduction was blocked by autophagy‑lysosome inhibitors (chloroquine, leupeptin, ammonium chloride) but not by the proteasome inhibitor MG132—implicating autophagolysosomal tau clearance as the dominant route.
  • ULK1 axis: PPP2R5C expression negatively tracked with phosphorylated ULK1; docking and co‑immunoprecipitation supported a PPP2R5C–ULK1 interaction consistent with regulation of autophagy initiation. This provides a mechanistic bridge between PPP2R5C, PP2A activity, and tau turnover.

Where a PPP2R5C assay could sit in care pathways

For health systems facing rising demand for dementia assessment and constrained specialist capacity, a PPP2R5C assay—if confirmed in larger, real‑world cohorts—would sit within an evolving biomarker ecosystem rather than replace existing tools.

  • Use case: As a minimally invasive blood marker, PPP2R5C could function as a pre‑screen alongside established plasma panels to prioritize patients for confirmatory PET or CSF testing, especially in primary care, community neurology, and telehealth triage models.
  • Reference standards: PET and CSF will remain arbiters for biologic confirmation. Several CSF assays for amyloid and tau have been cleared for clinical use in the U.S., providing a regulatory and clinical reference framework against which any new plasma test would be judged.
  • Analytical readiness: Transition from NDE‑based discovery to total plasma is promising, but laboratories will require harmonized pre‑analytical handling (collection tubes, processing times, freeze–thaw control) and cross‑platform calibration to keep between‑site variability low enough for clinical decision-making.
  • Regulatory pathway: Most blood‑based Alzheimer’s assays currently reach patients as laboratory‑developed tests under the Clinical Laboratory Improvement Amendments (CLIA), overseen by the Centers for Medicare & Medicaid Services via the CLIA regulatory framework. A PPP2R5C assay intended for diagnosis at scale would likely require in‑vitro diagnostic clearance, with robust multicenter evidence, if sponsors seek broader distribution beyond a small number of reference laboratories.
  • Coverage dynamics: Payer decisions increasingly hinge on analytical validity, clinical validity, and clinical utility. Evidence that PPP2R5C improves triage efficiency, shortens time to accurate diagnosis, or reduces downstream imaging and lumbar puncture demand would be decision‑relevant for public and private insurers.

Equity and system‑capacity considerations

The emergence of another blood‑based Alzheimer’s marker also raises distributional questions: who gets access first, and on what terms.

  • Access points: Primary‑care‑orderable blood tests can broaden entry to cognitive evaluation where neurology capacity is constrained, particularly in rural and underserved urban settings where PET and specialist memory clinics are scarce.
  • Population fit: The study emphasizes the need for larger, longitudinal, and ethnically diverse cohorts to ensure generalizability and to detect performance shifts across age, sex, and comorbidity profiles. Without this, PPP2R5C‑based decisions could entrench diagnostic inequities.
  • Operational load: If adopted, laboratories would need validated reference ranges, quality‑control materials, and staff training to maintain low coefficients of variation at clinically relevant cutoffs, adding to workforce and capital planning for health systems.
  • Ethical guardrails: Early biomarker positivity in people with minimal or no symptoms raises counseling and data‑privacy questions. Health systems should align communications, consent processes, and data governance with best practices for preclinical risk disclosure and genetic/familial counseling where relevant.

Key uncertainties and validation priorities

For now, PPP2R5C remains an experimental marker with clear promise but significant evidence gaps that regulators, payers, and clinical guideline writers will expect sponsors to address.

  • Stage discrimination: The AUROC of 0.5931 for aMCI vs. AD indicates limited staging utility; clinical value may center on early‑stage detection (identifying individuals on an Alzheimer’s trajectory) rather than fine‑grained classification within the dementia spectrum.
  • Comparators: Head‑to‑head performance against p‑tau‑based blood panels and in combination models (multi‑analyte scores that integrate amyloid, tau, and neurodegeneration markers) remains to be established.
  • Confounders: Systemic inflammation, renal function, concurrent neurodegenerative conditions, and commonly prescribed medications should be evaluated for analytical and clinical interference, including false‑positive and false‑negative patterns.
  • Neuropathological alignment: Prospective studies linking plasma PPP2R5C trajectories to longitudinal tau PET, CSF markers, and conversion from aMCI to AD will be critical to demonstrate clinical utility and to support health‑economic modeling.
  • Assay standardization: Shared calibrators, reference intervals, and external proficiency testing are prerequisites for broad deployment and for inclusion in clinical guidelines and reimbursement policies.

What to monitor as evidence matures

Over the next several years, PPP2R5C’s trajectory will depend less on its initial biological plausibility and more on how it performs under real‑world and regulatory scrutiny.

  • Multicenter, diverse cohorts with pre‑specified endpoints and blinded analyses, designed to satisfy regulatory and guideline expectations.
  • Reproducibility across platforms and laboratories, including lot‑to‑lot stability and inter‑run precision, to support consistent use across regions and health systems.
  • Integration into multi‑marker algorithms that combine PPP2R5C with p‑tau and neurodegeneration measures, potentially enhancing risk stratification for disease‑modifying therapies.
  • Regulatory and reimbursement milestones that define where PPP2R5C fits alongside existing biomarker pathways and emerging Alzheimer’s treatments—from early coverage policies to its appearance (or absence) in formal clinical practice guidelines.

For readers seeking foundational explanations of biomarker science in neurodegeneration, see this overview of biomarkers from the National Institute on Aging.

0 comments
0 FacebookTwitterPinterestEmail
Health

Blood-Based Proteomics for Effective Triage of Non-Specific Symptoms in Cancer Diagnosis

by Claire Donovan
written by Claire Donovan

Blood-based proteomics shows promise for triaging hard‑to‑explain symptoms

A Swedish research team has reported that a simple blood draw, analyzed with large‑scale proteomics, can help flag cancer among patients who present with non‑specific symptoms such as fatigue, pain, or weight loss. The study, conducted across Diagnostic Centres at Danderyd Hospital and Örebro University Hospital with collaborators at Karolinska Institutet, KTH Royal Institute of Technology, and SciLifeLab Uppsala, identified a protein signature linked to an eventual cancer diagnosis and built a model that distinguished cancer from inflammatory, autoimmune, and infectious conditions. The work was published in Nature Communications in 2025.

“The study shows the potential of large-scale proteomics for extracting clinically relevant information from small amounts of blood,” says Mikael Åberg, associate professor at Uppsala University and head of SciLifeLab Affinity Proteomics Uppsala, where the analyses were performed.

“A particular strength of the study is that the control group consisted largely of patients with other serious conditions that can cause symptoms similar to cancer,” says Charlotte Thålin, senior physician at Danderyd Hospital, adjunct professor at Karolinska Institutet and principal investigator for the study. “This reflects the clinical reality, where patients with non-specific symptoms are often difficult to assess.”

Study at a glance: setting, methods, and intended use

At the heart of the work is a question facing many health systems: can routinely collected blood samples be leveraged to make earlier, safer decisions about which patients with worrying but vague symptoms should move fastest through cancer pathways?

Feature Details
Patient cohort Blood samples from nearly 700 adults referred for non‑specific symptoms such as fatigue, pain, weight loss, or general deterioration.
Care setting Diagnostic Centres at Danderyd Hospital and Örebro University Hospital (Sweden), which receive referrals from primary care and other specialties.
Sample timing Baseline blood draw at first visit, before diagnostic investigations such as imaging or biopsy began.
Proteomic scope Quantification of 1,463 plasma proteins using a high‑plex affinity‑based platform.
Key output Protein signature associated with an eventual cancer diagnosis; a multivariable model that differentiated cancer from other serious conditions.
Intended clinical role Decision‑support for triage and prioritization in structured diagnostic pathways; explicitly not a replacement for imaging, histopathology, or multidisciplinary review.
Next step Prospective testing in primary care, where cancer prevalence is lower than in specialty settings and false positives carry greater system‑wide consequences.

Triage, not diagnosis: integrating with imaging and pathology

The investigators emphasize that this approach is designed to assist triage in symptom‑based pathways rather than to supplant confirmatory diagnostics. In practice, a proteomic readout could inform which patients warrant rapid escalation to imaging or specialist review while sparing others from unnecessary procedures and radiation exposure.

“The method could help identify which patients should be prioritised for further diagnostics, for example with PET-CT, while avoiding unnecessary investigations in patients without cancer.”

Fredrika Wannberg, resident at Danderyd Hospital and doctoral student at Karolinska Institutet

For hospital leaders, the proposition is that a standardized blood‑based signal-interpreted alongside clinical assessment and existing risk tools-could support more consistent decisions about who enters fast‑track cancer work‑ups and who can be safely observed or investigated stepwise.

Why health systems are interested in non‑specific symptom pathways

Symptom‑based cancer pathways-sometimes organized as “diagnostic centres” that accept referrals for vague but concerning presentations-aim to shorten time to diagnosis while managing finite imaging and specialist capacity. Sweden, Denmark, and the United Kingdom have built variants of this model; the NHS has deployed Rapid Diagnostic Centres for patients with non‑specific symptoms to reduce multiple sequential referrals and delays.

  • Diagnostic uncertainty often drives repeated tests, fragmented referrals, and delayed rule‑in/rule‑out decisions.
  • Non‑specific symptoms are common in primary care; only a minority reflect cancer, which highlights the need for high‑specificity triage tools that avoid overloading specialist services.
  • Downstream capacity limits-particularly PET‑CT slots and pathology workforce-make prioritization tools attractive if they can maintain safety and public trust.

For context, readers can find NHS information on non‑specific symptom services through its publicly available materials on Rapid Diagnostic Centres.

Potential impact on capacity, equity, and safety

If validated prospectively, a proteomic triage tool could have consequences not just for individual patients but for how cancer pathways are governed and financed.

  • Capacity management
    • More efficient allocation of PET‑CT and urgent imaging for higher‑risk patients, informing local prioritization protocols.
    • Reduced use of invasive diagnostics in lower‑risk groups when supported by clinical judgment and safety‑net follow‑up.
  • Equity considerations
    • Standardized algorithms may help reduce variability across clinics, but deployment must account for demographics, comorbidities, and social determinants to avoid embedding bias.
    • Access to phlebotomy, cold‑chain logistics, and rapid laboratory turn‑around in rural or under‑resourced settings remains a practical constraint for health authorities.
  • Patient‑safety guardrails
    • Use as adjunctive triage only; abnormal results should prompt guideline‑consistent evaluation, and normal results must not delay care when clinical suspicion is high.
    • Transparent cut‑offs, reproducibility, and independent external validation are essential before routine use or reimbursement decisions.

Implementation prerequisites across health systems

Moving from proof‑of‑concept to routine practice will require alignment between clinicians, regulators, and payers. Health‑system leaders considering proteomic triage tests will be looking for evidence and safeguards in several domains:

Domain Requirements for responsible deployment
Analytical validity Robust assay performance across laboratories; quality control for high‑plex protein panels; lot‑to‑lot reproducibility; standard operating procedures for sample handling.
Clinical validation Prospective, multi‑site studies in primary care and diverse populations; reporting of sensitivity, specificity, and predictive values with confidence intervals and pre‑specified endpoints.
Clinical utility Evidence that triage with proteomics shortens time to diagnosis, optimizes imaging use, and maintains or improves stage‑at‑diagnosis and survival outcomes.
Workflow integration Clear referral thresholds embedded in national or regional cancer pathways, electronic decision‑support, and feedback loops with imaging, pathology, and primary care services.
Data governance Privacy protections for biomarker data; transparent model development, audit trails, and monitoring for drift or performance degradation over time.
Cost and payment Budget impact analyses for laboratories and imaging services; payer coverage policies aligned to demonstrated clinical utility and agreed value‑based criteria.

Regulatory pathways and oversight touchpoints

Because proteomic signatures are likely to be deployed as regulated in vitro diagnostics rather than informal research tools, the governance landscape matters as much as the underlying biology.

  • European Union
    • In vitro diagnostic devices, including proteomic assays, fall under the In Vitro Diagnostic Medical Devices Regulation (IVDR), which raises evidentiary requirements for clinical performance and post‑market surveillance.
    • Hospitals pursuing in‑house assays must meet defined conditions on risk management, quality systems, and demonstration that equivalent commercial devices cannot meet local needs.
  • United States
    • Clinical laboratories typically validate tests under CLIA requirements; broader market access often involves US Food and Drug Administration review for safety and effectiveness.
    • Coverage and reimbursement can depend on demonstration of clinical utility, with evaluation by public and private payers that are increasingly focused on early‑diagnosis initiatives and value‑based cancer care.

Primary care testing will be the critical proof point

The research team plans to assess performance in primary care, where the pretest probability of cancer is substantially lower than in specialist clinics. That setting will stress‑test how well a proteomic signature preserves specificity while remaining sensitive to early disease-and whether it is acceptable to frontline clinicians and patients.

  • Key evaluation metrics
    • Diagnostic yield among low‑prevalence populations.
    • Impact on time to first imaging and time to diagnosis, compared with existing non‑specific symptom pathways.
    • Rates of false reassurance, missed cancers, and unnecessary escalation.
  • System outcomes
    • Changes in PET‑CT utilization and wait times.
    • Downstream biopsy rates and stage distribution at diagnosis.
    • Effects on patient‑reported experience measures in primary care and cancer services.

Funding and institutional backing

The study drew on a mix of public and philanthropic support, signaling interest from major Scandinavian research funders in proteomics‑enabled diagnostics and data‑driven pathway design.

  • Public and philanthropic support included:
    • Swedish Research Council
    • Knut and Alice Wallenberg Foundation
    • Jochnick Foundation

Bottom line for health leaders

As of January 2026, high‑plex plasma proteomics is emerging as a practical tool to help clinicians triage non‑specific symptoms within structured diagnostic pathways. The Swedish study demonstrates feasibility and face validity in real‑world referral populations, with authors underscoring that imaging and biopsy remain the cornerstones of cancer diagnosis.

For health‑system executives, regulators, and payers, the technology will be judged less on its novelty and more on whether it can be integrated into existing cancer strategies without widening inequities or undermining safety. The next phase-prospective evaluation in primary care with rigorous reporting, external validation, and clear health‑system metrics-will determine whether this approach can be adopted safely, equitably, and at scale.

0 comments
0 FacebookTwitterPinterestEmail